Hospital Universitario De Jaen — Clinical Trial Site

131 Registered trials

50 Currently recruiting

Organisation

Hospital Universitario De Jaen

Location

Jaen, Spain

Identifier

ORG-100041196

Address

Avenida Del Ejercito Espanol 10, 23007, Spain

Departments

034028: Oncología Médica
1201: Oncología Médica
1212:Oncología Médica
Allergy
Angiology and Vascular Sugery
Cardiology
Cardiology department
Dermatology
Endocrinología y Nutrición
ESP011:Oncología Médica
Hematología
Hematology
Hospital Universitario de Jaén
HU de Jaén_Cardiología
Infectious Diseases
Internal Medicine
Medica Oncology
Medical Oncology
Medical Oncology Department
Medicina Interna
Oncolgy
Oncología
Oncología Médica
Oncology
Oncology department
Oncology service
Servicio de Angiología y Cirugía vascular
Servicio de Cardiologia
Servicio de Oncologia
Servicio de Oncología Médica
UCG Enfermedades Infecciosas, Microbiología y Medicina preventiva
UGC Cuidados Intensivos
Unidad de Gestion Clinica de Oncologia Medica
Urology
Vascular Risk

Clinical trials at this site (131)

Search interface

A clinical study to test the effect of niraparib and immunotherapy, for patients with small cell lung cancer (SCLC) that is positive for SLF… Recruiting

2022-502092-33-00 Extensive-disease small cell lung cancer and high SLFN1 4 2024-05-31
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced… Recruiting

2023-503865-48-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 4 2024-02-16
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting

2022-500967-11-00 Previously Untreated Metastatic or Unresectable Melanom 5 2023-07-06
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoemboli… Recruiting

2024-512953-26-00 intermediate-stage hepatocellular carcinoma 5 2021-07-06
A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli… Recruiting

2024-512671-12-00 Unresectable head and neck squamous cell carcinoma, met 10 2021-03-05
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part… Ended

2024-515740-23-00 Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 5 2025-03-25
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother… Ended

2024-511957-23-00 Recurrent or Persistent Endometrial Cancer 5 2025-01-03
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec… Ended

2023-505617-24-00 Recurrent Ovarian Cancer with High Folate Receptor-Alph 4 2024-11-05
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
Clinical trial to assess the efficacy and safety of a vaccine for grasses and olive tree allergy Ended

2024-514525-34-00 Aetiological treatment of moderate-severe intermitent o 5 2024-08-18
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended

2023-508235-31-00 Atopic Dermatitis 5 2024-06-17
A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs ar… Ended

2023-508459-37-00 HER2-positive advanced solid tumours 1 2024-05-28
A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended

2023-506669-70-00 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR- 5 2024-04-30
Clinical trial to evaluate the safety and efficacy of a 7-day versus 14-day treatment for enterococcal infections. Ended

2023-508456-18-00 Uncomplicated bacteremia caused by E. faecalis or E. fa 6 2024-04-29
Randomized open-label Phase 2 trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adver… Ended

2023-505863-35-00 EGFR-mutated Advanced or Metastatic Non-small Cell Lung 4 2024-03-20
Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer p… Ended

2023-507438-25-00 Non-small cell lung cancer 2 2024-02-28